Flexadin is Vetoquinol’s line of joint-support supplements for dogs and cats, and its flagship product, Flexadin Advanced, is built around UC-II undenatured type II collagen rather than the glucosamine-and-chondroitin combination most joint chews use. That single difference is the whole reason the range exists: UC-II is dosed in single-digit milligrams and is thought to work through the immune system, not by supplying cartilage raw materials. Whether that mechanism translates into a difference your dog can feel is a fair question, and the published canine evidence is real but thinner than the marketing suggests.
This is an independent look at the Flexadin range: what each product actually contains according to Vetoquinol’s own published labels, how UC-II differs mechanistically from the ingredients you already know, what the peer-reviewed dog trials found, and where the evidence runs out.
Answer box. Flexadin is a veterinary-brand joint supplement family from Vetoquinol. Flexadin Advanced uses UC-II undenatured type II collagen (US label: 40 mg UC-II chicken cartilage per 3 g chew, yielding 10 mg total collagen), given as one chew a day regardless of the dog’s size, with no loading period stated on the label. Flexadin Plus is a different concept entirely — a glucosamine-based chew dosed by body weight. Four published canine trials support UC-II, but they are small, and a 2022 meta-analysis rated collagen evidence in dogs as weak overall. Discuss any joint supplement with your veterinarian, especially if your dog is already on pain medication.
What is Flexadin, and who makes it?
Flexadin is a brand owned by Vetoquinol, a French family-owned veterinary pharmaceutical company. The name covers several distinct formulas that share almost nothing in common except a logo, which is where most buyer confusion starts. In the United States, Vetoquinol’s own retail store currently lists four Flexadin products: Flexadin Advanced with UC-II for dogs and cats, a cat-specific Flexadin chew, Flexadin Plus Mini and Flexadin Plus Maxi. A separate Flexadin Advanced Extra Strength is marketed through Vetoquinol’s veterinary channel rather than that retail store.
The naming is genuinely inconsistent across markets, and this matters if you compare labels found online. The Canadian Flexadin Advanced label lists Boswellia serrata (85% boswellic acid) at 190 mg per 3 g chew alongside the chicken cartilage, while the US Flexadin Advanced label contains no boswellia at all — its stated actives are the chicken cartilage and the collagen it yields, with fish oil, flaxseed oil and vitamin E listed among the inactive ingredients. Same product name, different formula, different country. Always read the label on the bag in front of you rather than a page from another region.
Two further lines carry the Flexadin name without appearing on the US retail store: Flexadin Advanced Extra Strength and Flexadin 4life. Neither manufacturer page could be retrieved during this review, so no ingredient amounts are quoted for either.
What is in each Flexadin product?
All figures below are transcribed verbatim from Vetoquinol-owned product pages.
| Product | Actives per chew (as stated on manufacturer’s label) | Chew size | Dosing approach | Where sold |
|---|---|---|---|---|
| Flexadin Advanced with UC-II (US) | Active ingredients per chew: UC-II chicken cartilage 40 mg; total collagen (including undenatured type II collagen) 10 mg. Fish oil, flaxseed oil and vitamin E appear on the label as inactive ingredients, with no amounts stated. | 3 g | One chew daily, any size cat or dog, unless otherwise directed by your veterinarian | Retail and clinics |
| Flexadin Advanced (Canada) | Boswellia serrata (85% boswellic acid) 190 mg; omega-3 from flaxseed oil 73 mg; chicken cartilage 40 mg (yielding 10 mg collagen, including undenatured type II collagen); vitamin E 23 mg (23 IU); omega-3 from fish oil 16 mg | 3 g | One chew daily | Canada |
| Flexadin Plus Maxi (US) | Glucosamine HCl (shrimp and crab) 900 mg; MSM 800 mg; creatine monohydrate 500 mg; Perna canaliculus green-lipped mussel 300 mg; vitamin E 50 IU; EPA 18 mg; DHA 12 mg; vitamin C 10 mg | 7.25 g | By body weight; label refers to the back of the package | Retail |
| Flexadin Plus, medium & large dogs (Canada) | Glucosamine HCl 500 mg; chondroitin sulfate 400 mg; devil’s claw (Harpagophytum procumbens) 150 mg; omega-3 from flaxseed oil 150 mg; omega-3 from fish oil 32 mg; vitamin E 22 mg (22 IU); manganese 12 mg | 5 g | By body weight | Canada |
| Flexadin Plus, cats & small dogs (Canada) | Glucosamine HCl 125 mg; chondroitin sulfate 100 mg; devil’s claw 37.5 mg; omega-3 from flaxseed oil 42 mg; dl-methionine 18 mg; omega-3 from fish oil 10 mg; vitamin E 5.5 mg (5.5 IU); manganese 3 mg | 1.5 g | By body weight | Canada |
Flexadin Advanced Extra Strength is not listed on Vetoquinol’s US retail store and its manufacturer page could not be retrieved during this review, so no amounts are quoted for it here. The same applies to Flexadin 4life. Where a figure could not be read off a Vetoquinol-owned page, it has been left out rather than estimated.
Two things jump out. First, “Flexadin Plus” in the US and “Flexadin Plus” in Canada are not the same supplement — the US Maxi chew contains no chondroitin and no devil’s claw, and instead adds MSM, creatine and green-lipped mussel. Second, the Advanced line is unusual in the category for using a flat dose: one chew for a Chihuahua and one chew for a Great Dane. Vetoquinol’s rationale is that UC-II works by an immune mechanism that is not weight-proportional. That is a real pharmacological argument, but it is worth knowing it is a mechanistic assumption rather than something established by dose-ranging trials in dogs of different sizes.
How does UC-II work differently from glucosamine and chondroitin?
Glucosamine and chondroitin are substrate ingredients. The reasoning is that supplying the building blocks of glycosaminoglycans supports cartilage maintenance, which is why they are dosed in hundreds or thousands of milligrams. If you want the longer version of that mechanism, our guide to how glucosamine works in dogs walks through it, and Cosequin’s glucosamine and chondroitin formula is the reference point most owners compare against.
UC-II is a different proposition. It is type II collagen processed at low temperature so the triple-helix structure stays intact — “undenatured.” The proposed mechanism is oral tolerance: small amounts of intact collagen presented to gut-associated lymphoid tissue are thought to modulate the immune response to the dog’s own joint collagen. Vetoquinol’s US product page describes it this way: undenatured type II collagen “targets the immune system in a process called oral tolerization,” which it compares to seasonal allergy treatment — exposing the body to a small amount of the causative source to desensitise the immune system. Because the mechanism is immunological rather than nutritional, the amounts involved are tiny, which is why a 10 mg figure sits next to a 900 mg glucosamine figure and is not a typo or a shortfall.
The practical consequences: the Advanced label states no loading period, one chew covers any body weight, and the chew is small. The trade-off is that you are buying into a mechanism with a smaller canine evidence base.
What does the research on UC-II in dogs actually show?
Four published canine studies are worth knowing, and they should be read as a body of suggestive but limited evidence.
| Study | Design | What was used | Reported finding | Evidence tier |
|---|---|---|---|---|
| DeParle et al., 2005, J Vet Pharmacol Ther | RCT, 15 obese-arthritic dogs, 3 groups, 90 days plus 30-day withdrawal | 0, 1 mg/day or 10 mg/day UC-II | Significant declines in overall pain, pain on limb manipulation and lameness after exertion; greater improvement at the higher amount; relapse after withdrawal; no adverse effects | Low (very small n, industry-linked) |
| D’Altilio et al., 2007, Toxicol Mech Methods | Placebo-controlled, 20 dogs in 4 groups, 120 days | 10 mg UC-II vs 2,000 mg glucosamine + 1,600 mg chondroitin vs both | UC-II alone reduced overall pain by a reported 62% at 120 days; combination group outperformed glucosamine + chondroitin alone; no changes in liver or kidney markers | Low (very small n, industry-linked) |
| Stabile et al., 2019, Veterinary Sciences | Randomized, controlled, prospective; 60 client-owned dogs, 30 days | UC-II 1 tablet/day vs robenacoxib 1 mg/kg/day | LOAD and mobility scores fell similarly in both groups (robenacoxib 31.5%, UC-II 32.7%) | Moderate (largest, real-world, active comparator) |
| Varney et al., 2021, Transl Anim Sci | 40 healthy Labrador Retrievers, placebo-controlled, 11-week exercise regimen | 40 mg UC-II (10 mg collagen type II) daily vs maltodextrin | Lower IL-6 after a 5 km run and lower COMP (a cartilage turnover marker) after a 16 km run in supplemented dogs | Moderate, but healthy working dogs, not arthritis patients |
A 2024 randomized, double-blind, placebo-controlled cross-over trial in PLOS One tested a chew combining UC-II with Boswellia serrata in dogs with mild to moderate osteoarthritis and reported improvement in owner-scored mobility from four weeks of administration. That combination matches the Canadian Flexadin Advanced formula more closely than the US one — a distinction most articles about Flexadin miss entirely.
Now the counterweight. A 2022 systematic review and meta-analysis in the International Journal of Molecular Sciences assessed 72 trials of natural health products in canine and feline osteoarthritis. It found clear analgesic efficacy for omega-3-enriched diets and omega-3 supplements, “a weak efficacy of collagen,” and “a very marked non-effect of chondroitin-glucosamine nutraceuticals.” An earlier systematic review in the Journal of Veterinary Internal Medicine reached a similar conclusion: evidence for nutraceuticals in osteoarthritis is generally poor, with omega-3 fatty acids in dogs the exception.
Read together: UC-II performs no worse than glucosamine and chondroitin in head-to-head canine work, and possibly better, but “better than an ingredient class that reviewers rate as ineffective” is a modest claim. The Stabile non-inferiority result against an NSAID is the single most interesting finding in the file, and it is one 30-day study that has not been replicated. A later study from the same group, comparing UC-II with the NSAID cimicoxib in 76 dogs over 30 days, reported LOAD score reductions of 31.4% for UC-II and 29.5% for cimicoxib, with both significantly lower than an untreated control group. That is a consistent picture across two trials from one research group — which is not the same thing as independent replication.
What should you realistically expect, and when?
The published trials give the only figures worth anchoring to. The 2007 study recorded a significant reduction in overall pain within 30 days (33%) with maximum reductions at 120 days (62%), and the 2024 cross-over trial detected owner-reported mobility improvement at four weeks of administration.
A sensible way to frame it, treating those as study observations rather than as a promise about your own dog:
- Weeks 1–2: essentially an acceptance test. Does your dog eat the chew reliably? Vetoquinol markets the Flexadin range with a palatability guarantee and a “95% of dogs love it” claim, footnoted to unpublished palatability studies held on file — a marketing figure, not a peer-reviewed one.
- Weeks 3–4: the earliest window in which the published trials detected owner-noticeable change. Absence of change here is not a failure.
- Weeks 8–12: the point at which the published studies recorded their larger effects. If nothing has shifted by now, that is meaningful information for your vet.
- After stopping: both 2005 and 2007 trials recorded a relapse of pain within the 30-day withdrawal period. Any benefit appears to depend on continued administration.
Track something objective rather than relying on impressions. Time how long your dog takes to stand from lying down, count stairs refused per week, or note whether they still want the last ten minutes of the walk. Structured home care for a dog with arthritis — traction on slick floors, ramps, controlled exercise — moves the needle more than any chew, and it makes supplement effects easier to see because the baseline is stable.
Common mistakes owners make with Flexadin
Comparing UC-II milligrams to glucosamine milligrams. A 10 mg figure next to a 900 mg figure looks like a shortfall. Different mechanism, different scale. This comparison is meaningless.
Assuming “Advanced” outranks “Plus.” They are different formulas for different reasoning, not tiers of the same product. Owners who want the classic glucosamine approach are buying the wrong bag when they pick Advanced.
Buying Extra Strength expecting a proportional effect. A higher-strength version exists, but its label could not be verified from a manufacturer page for this article, and no published canine trial has compared two UC-II amounts within the Flexadin range head to head. Ask your veterinary practice to show you the actual panel before paying more for it.
Stacking without telling the vet. Adding Flexadin to an existing chew can duplicate omega-3, vitamin E or glucosamine loads. If you are weighing options across brands, our overview of supplements studied for canine arthritis and our broader piece on comparing joint supplements for dogs lay out what overlaps.
Treating a supplement as pain control. In the one trial where UC-II matched an NSAID, that was a controlled 30-day comparison in dogs with osteoarthritis under veterinary supervision. It is not a licence to stop prescribed medication.
Myth vs fact
| Claim you’ll see online | What the sources support |
|---|---|
| “UC-II is clinically proven better than glucosamine and chondroitin” | One small 2007 trial (20 dogs) reported greater pain reduction with UC-II. Independent reviewers rate the overall collagen evidence in dogs as weak. |
| “Undenatured collagen rebuilds cartilage” | Not established. The proposed mechanism is immune modulation, and no canine trial has demonstrated cartilage regrowth. |
| “One chew for any dog size can’t be right” | It follows the immune-tolerance rationale and is what the manufacturer’s label states. It is a mechanistic argument, not a dose-ranging finding. |
| “Supplements can replace weight management” | Veterinary sources consistently place weight normalization and exercise modification first in osteoarthritis management. |
When to call your vet
Speak to your veterinarian before starting Flexadin or any joint supplement if your dog:
- is already taking an NSAID, gabapentin, a monoclonal antibody for osteoarthritis pain, or any prescription medication
- has a known chicken or fish allergy — the Advanced chews are chicken cartilage and chicken liver based, and both lines contain fish or flaxseed oil
- has liver or kidney disease, a clotting disorder, or is scheduled for surgery (omega-3 and devil’s claw both warrant a conversation here)
- is pregnant, nursing, or under a year old
- has a history of pancreatitis, given the added oils
Call promptly, rather than waiting, if your dog develops sudden non-weight-bearing lameness, a hot or swollen joint, yelping on touch, appetite loss, vomiting or diarrhea after starting a new chew, or a rapid decline in mobility. Sudden change is not what osteoarthritis normally does, and a supplement should never be the reason a diagnosis gets delayed.
Frequently asked questions
Is Flexadin better than Cosequin or Dasuquin for dogs?
They work by different proposed mechanisms, so “better” depends on which you want to try. Cosequin and Dasuquin are glucosamine-and-chondroitin based; Flexadin Advanced is UC-II based. The single canine head-to-head study of UC-II versus glucosamine plus chondroitin favoured UC-II, but it enrolled only 20 dogs.
How long does Flexadin take to work in dogs?
The published canine trials detected owner-noticeable change at around four weeks, a significant reduction in overall pain by 30 days in the 2007 study, and the largest reductions at 90 to 120 days. Those are study observations, not a schedule for your dog. Follow your product label or your veterinarian’s guidance on duration.
Does Flexadin need a loading dose?
The Flexadin Advanced label states no loading period: one chew daily for any size cat or dog from the start. Vetoquinol’s UK Flexadin Plus page, by contrast, states that the daily amount should be doubled for the first 4–6 weeks of use, as it says is the case for most glucosamine and chondroitin products.
Is Flexadin safe for dogs?
In the published canine trials, no adverse effects were reported and no significant changes were seen in liver or kidney markers over 90 to 120 days. Those studies were small. Dogs with chicken or fish allergies, or on other medication, should be cleared by a vet first.
Do I need a prescription for Flexadin?
No. Flexadin Advanced and Flexadin Plus are supplements sold over the counter, including on Vetoquinol’s own US store. A separate Extra Strength version of Flexadin Advanced is marketed through Vetoquinol’s veterinary channel rather than that retail store, so you may need to ask your practice for it.
Can Flexadin replace my dog’s arthritis medication?
No. One 30-day study found UC-II improved mobility scores similarly to robenacoxib, but that is a single trial, and changing or stopping prescribed pain medication is a veterinary decision.
References
- DeParle LA, Gupta RC, Canerdy TD, et al. “Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs.” Journal of Veterinary Pharmacology and Therapeutics, 2005;28(4):385–390. PMID 16050819. DOI: 10.1111/j.1365-2885.2005.00668.x — https://pubmed.ncbi.nlm.nih.gov/16050819/
- D’Altilio M, Peal A, Alvey M, et al. “Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs.” Toxicology Mechanisms and Methods, 2007;17(4):189–196. PMID 20020968. DOI: 10.1080/15376510600910469 — https://pubmed.ncbi.nlm.nih.gov/20020968/
- Stabile M, Samarelli R, Trerotoli P, et al. “Evaluation of the Effects of Undenatured Type II Collagen (UC-II) as Compared to Robenacoxib on the Mobility Impairment Induced by Osteoarthritis in Dogs.” Veterinary Sciences, 2019;6(3):72. PMID 31487772. DOI: 10.3390/vetsci6030072 — https://pubmed.ncbi.nlm.nih.gov/31487772/
- Varney JL, Fowler JW, Coon CN. “Undenatured type II collagen mitigates inflammation and cartilage degeneration in healthy Labrador Retrievers during an exercise regimen.” Translational Animal Science, 2021;5(2):txab084. PMID 34124592. DOI: 10.1093/tas/txab084 — https://pmc.ncbi.nlm.nih.gov/articles/PMC8191485/
- “Effects of a feed supplement, containing undenatured type II collagen (UC II) and Boswellia Serrata, in the management of mild/moderate mobility disorders in dogs: A randomized, double-blind, placebo controlled, cross-over study.” PLOS ONE, 2024. PMID 39475935. DOI: 10.1371/journal.pone.0305697 — https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0305697
- Barbeau-Grégoire M, Otis C, Cournoyer A, Moreau M, et al. “A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis.” International Journal of Molecular Sciences, 2022;23(18):10384. PMID 36142319. DOI: 10.3390/ijms231810384 — https://pmc.ncbi.nlm.nih.gov/articles/PMC9499673/
- Stabile M, Lacitignola L, Samarelli R, Fiorentino M, Crovace A, Staffieri F. “Evaluation of clinical efficacy of undenatured type II collagen supplementation compared to cimicoxib and their association in dogs affected by natural occurring osteoarthritis.” Research in Veterinary Science, 2022. PMID 35853328. DOI: 10.1016/j.rvsc.2022.06.030 — https://pubmed.ncbi.nlm.nih.gov/35853328/
- Vandeweerd JM, Coisnon C, Clegg P, et al. “Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis.” Journal of Veterinary Internal Medicine, 2012;26(3):448–456. PMID 22404506. DOI: 10.1111/j.1939-1676.2012.00901.x — https://pubmed.ncbi.nlm.nih.gov/22404506/
- MSD/Merck Veterinary Manual. “Osteoarthritis in Dogs and Cats.” — https://www.msdvetmanual.com/musculoskeletal-system/osteoarthritis-in-dogs-and-cats/osteoarthritis-in-dogs-and-cats
Product label sources (each page retrieved and read for this article, August 2026): Vetoquinol Pets USA, “Flexadin Advanced with Undenatured Type II Collagen Joint Chews for Dogs and Cats” (https://www.vetoquinolpetsusa.com/products/flexadin-advanced-with-uc-ii-joint-chews-for-dogs-and-cats); Vetoquinol Pets USA, “Flexadin Plus Maxi Joint Support Chews with Glucosamine, 90-count bag” (https://www.vetoquinolpetsusa.com/products/vetoquinol-flexadin-plus-maxi-joint-support-chews-with-glucosamine-90-count-bag); Flexadin Canada, “Flexadin Advanced” (https://www.flexadin.ca/en/product/flexadin-advanced/); Flexadin Canada, “Flexadin Plus” (https://www.flexadin.ca/en/product/flexadin-plus/); Vetoquinol Pet UK, “Flexadin Plus” (https://www.vetoquinolpet.co.uk/products/physical-well-being/flexadin-plus).
Veterinary disclaimer. This article is for general educational purposes and does not constitute veterinary advice, diagnosis or treatment. Dog Health Insider is an independent publication and is not affiliated with Vetoquinol. Supplements are not medicines and are not intended to diagnose, treat, cure or prevent any disease. Always follow your product label and consult a licensed veterinarian before starting, stopping or changing any supplement or medication for your dog.